Notably, IL-1 has emerged as a critical driver of bone erosion via nucleotide- binding oligomerization domain 3 (NLRP3) inflammasome activation, underscoring its therapeutic potential for refractory RA and structural damage mitigation. This evidence concerns the gene IL1A and rheumatoid arthritis.